InMed Pharmaceuticals

Investment summary

InMed has initiated a Phase II trial for INM-755 in up to 20 epidermolysis bullosa (EB) patients with an anticipated treatment duration of 28 days. Patients with all four subtypes of inherited EB, EB Simplex, Dystrophic EB, Junctional EB and Kindler syndrome will be eligible for the trial. Current expectations are for the trial to enroll in approximately a year. Additionally, the company recently acquired BayMedica, a private US-based company that is focusing on the manufacture and commercialization of rare cannabinoids. The combined company has multiple tools to produce rare cannabinoids at meaningful yields and at attractive costs and has a growing commercial product.